A5038098413- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Systemic Sclerosis and Related Diseases
- Inflammatory Myopathies and Dermatomyositis
- Sarcoidosis and Beryllium Toxicity Research
- Pulmonary Hypertension Research and Treatments
- Medical Imaging and Pathology Studies
- Eosinophilic Disorders and Syndromes
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Rheumatoid Arthritis Research and Therapies
- Respiratory and Cough-Related Research
- Immunodeficiency and Autoimmune Disorders
- Connective Tissue Growth Factor Research
- Dermatologic Treatments and Research
- Systemic Lupus Erythematosus Research
- Pleural and Pulmonary Diseases
- Pneumocystis jirovecii pneumonia detection and treatment
- Voice and Speech Disorders
- Heart Failure Treatment and Management
- Vasculitis and related conditions
- Tracheal and airway disorders
- Lung Cancer Treatments and Mutations
- Occupational and environmental lung diseases
- Transplantation: Methods and Outcomes
- Asthma and respiratory diseases
- Tuberculosis Research and Epidemiology
Bristol-Myers Squibb (United States)
2019-2025
Maastricht University Medical Centre
2024
Hospital Universitari Germans Trias i Pujol
2024
University of Colorado Denver
2011-2020
University of Colorado Anschutz Medical Campus
2016-2019
KU Leuven
2019
Hôpital Louis Pradel
2019
University of Padua
2019
Royal Brompton Hospital
2019
Pulmonary and Critical Care Associates
2019
About 90 percent of human pancreatic carcinomas show allelic loss at chromosome 18q. To identify candidate tumor suppressor genes on 18q, a panel were analyzed for convergent sites homozygous deletion. Twenty-five 84 tumors had deletions 18q21.1, site that excludes DCC (a gene colorectal cancer) and includes DPC4 , similar in sequence to Drosophila melanogaster ( Mad ) implicated transforming growth factor-β (TGF-β)-like signaling pathway. Potentially inactivating mutations identified six 27...
Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and leading cause sclerosis–related death. Nintedanib, tyrosine kinase inhibitor, has been shown to have antifibrotic antiinflammatory effects in preclinical models ILD.
Many patients with an idiopathic interstitial pneumonia (IIP) have clinical features that suggest underlying autoimmune process but do not meet established criteria for a connective tissue disease (CTD). Researchers proposed differing and terms to describe these patients, lack of consensus over nomenclature classification limits the ability conduct prospective studies uniform cohort. The “European Respiratory Society/American Thoracic Society Task Force on Undifferentiated Forms Connective...
Mortality rates from rheumatoid arthritis-associated interstitial lung disease (RA-ILD) are largely unknown.We sought to determine mortality in the United States 1988 through 2004.Using data National Center for Health Statistics, we calculated age-adjusted deaths of persons with disease, determined prevalence all decedents arthritis, and compared age underlying cause death these two cohorts decedents.From 2004, there were 39,138,394 U.S. residents 162,032 deaths. Of deaths, 10,725 (6.6%) met...
Given the phenotypic similarities between rheumatoid arthritis (RA)–associated interstitial lung disease (ILD) (hereafter, RA-ILD) and idiopathic pulmonary fibrosis, we hypothesized that strongest risk factor for development of gain-of-function MUC5B promoter variant rs35705950, would also contribute to ILD among patients with RA.
Objective. Small series suggest mycophenolate mofetil (MMF) is well tolerated and may be an effective therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD). We examined the tolerability longitudinal changes in pulmonary physiology a large diverse cohort of patients with CTD-ILD treated MMF. Methods. identified consecutive evaluated at our center between January 2008 2011 prescribed MMF CTD-ILD. assessed safety used data analyses to examine over time, before...
Interstitial lung disease (ILD) is a common pulmonary manifestation of rheumatoid arthritis. There lack clarity around predictors mortality and behaviour over time in these patients.We identified arthritis-related interstitial (RA-ILD) patients evaluated at National Jewish Health (Denver, CO, USA) from 1995 to 2013 whose baseline high-resolution computed tomography (HRCT) scans showed either nonspecific pneumonia (NSIP) or "definite" "possible" usual (UIP) pattern. We used univariate,...
Patients with interstitial lung disease (ILD) may have features of connective tissue (CTD), but lack findings diagnostic a specific CTD. A recent European Respiratory Society/American Thoracic Society research statement proposed criteria for patients pneumonia autoimmune (IPAF). We applied IPAF to idiopathic and undifferentiated CTD-ILD (UCTD). then characterised the clinical, serological morphological cohort, compared outcomes other ILD cohorts validated individual domains using survival as...
Objective. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This study was designed to evaluate the tolerability IPF treatment pirfenidone in SSc-ILD. The known gastrointestinal, skin, liver adverse events (AE) are importance given involvement these organs SSc. Methods. All patients received were randomized 1:1 either 2- or 4-week titration starting at 801 mg/day...
Objective: Some patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) develop a progressive fibrosing phenotype. We investigated the diagnosis and management of non-IPF ILDs using data from survey physicians US insurance claims. Methods: Pulmonologists, rheumatologists internists in France, Germany, Italy, Japan, Spain, UK who had managed ≥10 past year, including those ILDs, completed an online survey. Data on prescription claims were obtained...
Objective. Interstitial lung disease (ILD) is commonly associated with rheumatoid arthritis (RA) and can have significant morbidity mortality. The objective of this study was to calculate the prevalence, incidence, healthcare costs, mortality RA-related ILD (RA-ILD) in United States. Methods. This retrospective cohort analysis used Truven Health MarketScan Commercial Medicare Supplemental health insurance databases from 2003 2014 Social Security Administration death database. Patients RA-ILD...
Objective To assess cumulative survival rates and identify independent predictors of mortality in patients with incident systemic sclerosis (SSc)–associated pulmonary arterial hypertension (PAH) who had undergone routine screening for PAH at SSc centers the US. Methods The Pulmonary Hypertension Assessment Recognition Outcomes Scleroderma registry is a prospective high risk or definite diagnosed by right‐sided heart catheterization within 6 months enrollment. Only World Health Organization...